Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking by unknown
This is a repository copy of Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 
identified through crystallographic screening and computational docking.




(2021) Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through 






This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Schuller et al., Sci. Adv. 2021; 7 : eabf8711     14 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 23
C O R O N A V I R U S
Fragment binding to the Nsp3 macrodomain of  
SARS-CoV-2 identified through crystallographic 
screening and computational docking
Marion Schuller1†, Galen J. Correy2†, Stefan Gahbauer3†, Daren Fearon4†, Taiasean Wu5,6,  
Roberto Efraín Díaz2,7, Iris D. Young2,8, Luan Carvalho Martins9, Dominique H. Smith10, 
Ursula Schulze-Gahmen8, Tristan W. Owens8, Ishan Deshpande8, Gregory E. Merz8, Aye C. Thwin8, 
Justin T. Biel8, Jessica K. Peters8, Michelle Moritz8, Nadia Herrera8, Huong T. Kratochvil8, 
QCRG Structural Biology Consortium8‡, Anthony Aimon4, James M. Bennett11, Jose Brandao Neto4,  
Aina E. Cohen12, Alexandre Dias4, Alice Douangamath4, Louise Dunnett4, Oleg Fedorov11,  
Matteo P. Ferla13, Martin R. Fuchs14, Tyler J. Gorrie-Stone4, James M. Holton12,15,16, Michael G. Johnson17, 
Tobias Krojer11,18, George Meigs15,16, Ailsa J. Powell4, Johannes Gregor Matthias Rack1,  
Victor L. Rangel11,18,19, Silvia Russi12, Rachael E. Skyner4, Clyde A. Smith12, Alexei S. Soares20, 
Jennifer L. Wierman12, Kang Zhu1, Peter O’Brien21, Natalia Jura22, Alan Ashworth10, John J. Irwin3, 
Michael C. Thompson23, Jason E. Gestwicki3,5, Frank von Delft4,11,18,24*, Brian K. Shoichet3*,  
James S. Fraser2*, Ivan Ahel1*
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) macrodomain within the nonstructural pro-
tein 3 counteracts host-mediated antiviral adenosine diphosphate–ribosylation signaling. This enzyme is a prom-
ising antiviral target because catalytic mutations render viruses nonpathogenic. Here, we report a massive 
crystallographic screening and computational docking effort, identifying new chemical matter primarily targeting 
the active site of the macrodomain. Crystallographic screening of 2533 diverse fragments resulted in 214 unique 
macrodomain-binders. An additional 60 molecules were selected from docking more than 20 million fragments, 
of which 20 were crystallographically confirmed. X-ray data collection to ultra-high resolution and at physiological 
temperature enabled assessment of the conformational heterogeneity around the active site. Several fragment 
hits were confirmed by solution binding using three biophysical techniques (differential scanning fluorimetry, 
homogeneous time-resolved fluorescence, and isothermal titration calorimetry). The 234 fragment structures 
explore a wide range of chemotypes and provide starting points for development of potent SARS-CoV-2 macro-
domain inhibitors.
INTRODUCTION
Macrodomains are conserved protein domains found in all kingdoms 
of life and in several viruses (1). Viral macrodomains recognize and 
remove host-derived adenosine diphosphate (ADP)–ribosylation, a 
posttranslational modification of host and pathogen proteins (2, 3). 
The innate immune response involves signaling by ADP-ribosylation, 
which contributes to the suppression of viral replication (3–7). Upon 
viral infection, ADP-ribosylation is catalyzed by an interferon- induced 
subset of mammalian ADP-ribosyltransferases, collectively termed 
“antiviral poly(ADP-ribosyl) polymerases” (PARPs) (3, 8). These en-
zymes transfer the ADP-ribose (“ADPr”) moiety of nicotinamide ad-
enine dinucleotide onto target proteins (3, 8). For example, during 
coronavirus (CoV) infection, PARP14 stimulates interleukin-4– 
dependent transcription, which leads to the production of proinflam-
matory, antiviral cytokines (9). Viral macrodomains, which are found 
primarily in corona, alpha, rubi, and herpes viruses, can counteract 
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this host defense mechanism via their (ADP-ribosyl)hydrolase activi-
ty, contributing to the host-viral arms race for control of cell sig-
naling (10).
CoVs are important pathogens of livestock and humans. Three 
strains of seven known to infect humans have caused major out-
breaks within the past two decades: the severe acute respiratory syn-
drome (SARS) CoV, causing the SARS epidemic from 2002 to 2004; 
the Middle East respiratory syndrome CoV, causing outbreaks in 
2012, 2015, and 2018; and SARS-CoV-2, causing the current CoV 
disease 2019 (COVID-19) pandemic (11). The coronaviral conserved 
macrodomain (called “Mac1” here; also known as “S2-MacroD” 
or “X domain”) is encoded as part of the nonstructural protein 3 
(Nsp3), a 200-kDa multidomain protein (12). While cell culture ex-
periments suggest that SARS Mac1 is dispensable for viral replica-
tion in some cell lines (5, 13, 14), animal studies have shown that its 
hydrolytic activity promotes immune evasion and that it is essential 
for viral replication and pathogenicity in the host (6, 7). The critical 
role of macrodomains is further supported by experiments using 
catalytic null mutations of the murine hepatitis virus, which render 
that virus essentially nonpathogenic (5, 6, 13). Collectively, these 
findings support the idea that SARS-CoV-2 Mac1 is a promising drug 
target for disrupting the viral life cycle.
A barrier for macrodomain drug discovery has been the lack of 
well-behaved inhibitors for this domain. Making matters worse, 
there are few biochemical assays suitable for screening for these in-
hibitors. Thus far, PDD00017273, an inhibitor of the poly(ADPr)
glycohydrolase (PARG), a macrodomain-type (ADP-ribosyl)hydrolase, 
remains the only well-characterized inhibitor with convincing on- 
target pharmacology and selectivity (15). The initial hit was found 
by a homogeneous time-resolved fluorescence (HTRF)–based assay 
that measures PARG activity, rendering the assay unsuitable for 
macrodomains that lack this activity (16). A selective allosteric in-
hibitor targeting PARP14 was identified in an AlphaScreen-based 
high-throughput screen (HTS) (17). While this inhibitor showed 
on-target activity in cells, its unique allosteric binding site is diffi-
cult to translate to other macrodomains. While potential Mac1 in-
hibitors have emerged with the advent of SARS-CoV-2 (18), their 
binding mechanisms and efficacy remain unclear, and the lack of a 
biochemical assay specific for Mac1 has hindered their development. 
Furthermore, structures of the new inhibitors bound to Mac1 have 
not yet been reported, making optimization of initial hits, however 
promising, difficult.
To address the lack of chemical matter against Mac1, we turned 
to fragment-based ligand discovery using crystallography as a pri-
mary readout (Fig. 1). Fragment screens can efficiently address a 
large and relatively unbiased chemical space (19). Despite typically 
weak overall affinity, fragments often have high ligand efficiency 
(LE) [−DGb/HAC (heavy atom count)] and can provide templates 
for further chemical elaboration into lead-like molecules (20). Crystal-
lography can be used as a primary screening method for fragment 
discovery (21), and recent automation and processing software at 
synchrotron radiation sources has made this routinely possible at 
facilities such as the XChem platform at Diamond Light Source 
(22–25). As part of Diamond Light Source’s contribution toward 
efforts to combat COVID-19, fragment screening expertise and in-
frastructure were made immediately available to any users working 
on SARS-CoV-2 targets (26). Similarly, synchrotron access for es-
sential COVID-19–related research was also made available at the 
U.S. Department of Energy light sources.
Because crystallographic fragment screens can generate hits that 
bind anywhere on the protein surface, we wanted to supplement 
those screens with molecular docking intentionally targeting the ac-
tive site. Docking has the additional benefit of exploring a much 
larger chemical space than an empirical fragment library. While an 
empirical library of ~1000 to 2000 fragments can represent a chem-
ical space as large as, or larger than, that of a classic HTS library of 
several million compounds, exploration of chemotypes, including 
those that are well suited to a particular target subsite, will inevita-
bly be limited (27). Conversely, docking a much larger virtual li-
brary allows finer-grained sampling around many chemotypes. A 
potential drawback of molecular docking is doubt about its ability 
to predict weakly binding fragment geometries with high fidelity. 
While docking has identified potent ligands from libraries of lead-
like molecules [250 to 350 atomic mass units (amu)] (28–30), these 
molecules offer more functional group handles for protein match-
ing than do most fragments (150 to 250  amu), and docking is 
thought to struggle with the smaller, less complex, and geometrical-
ly more promiscuous fragments (31). Thus, the pragmatism of this 
approach has been uncertain (32, 33).
Here, we present a combination of experimental crystallographic- 
based and computational docking–based fragment screens per-
formed against Nsp3 Mac1 of SARS-CoV-2 (Fig. 1). Using x-ray 
crystallography, we screened fragment libraries of 2533 compounds, 
yielding 214 unique fragment-bound Mac1 structures at atomic reso-
lution. Docking of more than 20 million compounds prioritized 
60 molecules for structure determination, yielding the structures of 
20 additional compounds bound to Mac1. Additional x-ray data 
collection to ultrahigh resolution and at physiological temperature 
illuminated the conformational heterogeneity in the Mac1 active 
site. We were able to confirm the binding of several fragments with 
differential scanning fluorimetry (DSF), isothermal titration calorim-
etry (ITC), and an HTRF-based ADPr-peptide displacement assay, 
validating the activity of these molecules and providing a founda-
tion for their optimization. The new fragments explore a wide range 
of chemotypes that interact with the catalytic site of Mac1. Togeth-
er, these results create a road map for inhibitor development against 
Mac1, which may help to combat the pathogenicity of SARS-CoV-2.
RESULTS
Two crystal forms of Nsp3 Mac1 reveal differences in active 
site accessibility
We sought a crystal system that enabled consistent ligand soaking 
for fragment screening and for testing docking predictions. Six Mac1 
crystal forms have previously been reported (data file S1). Initially, 
we designed a construct based on Protein Data Bank (PDB) entry 
6VXS (34). This construct has been reported to crystallize in P1, C2, 
and P21 with either one or two molecules in the asymmetric unit 
(ASU) (data file S1). This construct crystallized reproducibly in C2 
with microseeding and diffracted to a maximum resolution of 0.77 Å 
(data file S1 and figs. S1 and S2A). This high-resolution data yielded 
electron density maps at true atomic resolution with abundant al-
ternative conformations (fig. S1). The electron density maps also 
revealed features that are rarely observed in macromolecular crys-
tallography, such as explicit hydrogen atoms, and covalent bond den-
sity (fig. S1). Although the active site appears accessible (fig. S3B), 
efforts to soak ADPr into the crystals were unsuccessful. In addition, 
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dimethyl sulfoxide (DMSO) tolerance (fig. S2A), which is problem-
atic for fragment soaking. In attempts to overcome this problem, we 
experimented with lysine methylation (35), which increased DMSO 
tolerance (fig. S2A) but unfortunately increased occlusion of the ac-
tive site (fig. S3, F and G), and dehydration, which increased DMSO 
tolerance, at the cost of nonisomorphism (fig. S2, A and C).
In parallel, we designed a new Mac1 construct that crystallized in 
P43 with two molecules in the ASU (data file S1). This construct 
crystallized reproducibly with microseeding and diffracted to a max-
imum resolution of 0.85 Å (data file S1). The sequence differences 
between the two constructs were slight (data file S1) yet resulted in 
a substantially different crystal packing (fig. S3, B to E). Although 
the active site of protomer B was obstructed, the active site of protomer 
A was accessible (fig. S3B), and we were able to soak ADPr into the 
crystals (fig. S4A). This new structure also revealed a notable differ-
ence compared to previously reported Mac1-ADPr structures: The 
a-anomer of the terminal ribose was observed instead of the b-anomer 
(fig. S4, A to D). Despite this, alignment of ADPr is excellent be-
tween all Mac1-ADPr structures (fig. S4D), and the structures are 
similar overall (fig. S4E). The DMSO tolerance of the P43 crystals 
was excellent (fig. S2A). Accordingly, most of our fragment soaking 
work proceeded with this construct.
Identifying new ligands for Nsp3 Mac1 using 
crystallographic fragment screening and docking
Characterization of experimental and virtual screening libraries
Crystal soaking screens at the XChem facility were performed with 
the P43 crystals and a collection of fragment libraries [e.g., Diamond 
Light Source, Structural Genomics Consortium (SGC), and iNEXT 
(DSI)–poised library including 687 molecules (36) and the EU- 
OPENSCREEN containing 968 molecules] totaling 2122 molecules 
(see data file S1 for details). Crystals were screened at the Diamond 
Light Source. At University of California San Francisco (UCSF), a 
fragment library composed of Enamine’s Essential Fragment library 
with 320 compounds, augmented by an additional 91 molecules 
from an in-house library (UCSF_91), was screened against both 
the P43 and C2 crystal forms at the Advanced Light Source (ALS), 
the Stanford Synchrotron Radiation Lightsource (SSRL), and the 
National Synchrotron Light Source II (NSLS-II). On average, mole-
cules across the XChem and UCSF collections had molecular weights 
of 192 ± 47 amu, cLogP values from −1.8 to 3.8, 13 ± 3 heavy atoms, 
and, on average, two rotatable bonds (fig. S5).
Two fragment libraries were computationally docked against the 
structure of Mac1 (PDB 6W02): a library of 722,963 fragments “in 
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Fig. 1. Overview of the fragment discovery approach for SARS-CoV-2 Nsp3 Mac1 presented in this study. (A) Surface representation of Nsp3 Mac1 with ADPr bound 
(cyan) in a deep and open binding cleft. (B) Nsp3 Mac1 has (ADP-ribosyl)hydrolase activity, which removes ADP-ribosylation modifications attached to host and pathogen 
targets. ADPr is conjugated through C1 of the distal ribose. (C) Summary of the fragment discovery campaign presented in this work. Three fragment libraries were 
screened by crystallography: two general-purpose [XChem and University of California San Francisco (UCSF)] and a third bespoke library of 60 compounds, curated for 
Mac1 by molecular docking of more than 20 million fragments. Crystallographic studies identified 214 unique fragments binding to Mac1, while the molecular docking 
effort yielded 20 crystallographically confirmed hits. Several crystallographic and docking fragments were validated by isothermal titration calorimetry (ITC), differential 
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of 20,006,175 mainly make-on-demand fragments that have not 
been previously synthesized, but can readily be made, available pre-
dominantly from Enamine and WuXi (34). Molecules from the 
ZINC15 fragment library had molecular weights of <250 amu, 
cLogP < 3.5, with an average of four rotatable bonds, and typically 
4 to 19 heavy atoms (fig. S5). In addition, an “in-human” library of 
20,726 drugs, investigational new drugs, and metabolites that have 
been tested in humans were included into the docking screen, with 
a view to potential repurposing opportunities. All three sets can be 
downloaded from ZINC15 (http://zinc15.docking.org) (37).
We investigated the fragment libraries for their diversity and 
their representation of chemotypes likely to bind at the adenine rec-
ognition site of Mac1 (fig. S5). Bemis-Murcko (BM) scaffold (38) 
analysis revealed 179 unique scaffolds in the UCSF libraries and 809 
such scaffolds in the XChem fragment libraries. The in-stock frag-
ment docking library contained 69,244 scaffolds, while 803,333 scaf-
folds were present in the entire ZINC15 20M fragment collection. 
Together, the experimentally screened libraries contained roughly 
two compounds per BM scaffold, while the docking libraries con-
tained approximately 10 fragments per scaffold, consistent with the 
expected higher granularity of the docking libraries afforded by their 
much larger size.
Because adenine-containing compounds are the only structurally 
characterized binders of Mac1 and fragment libraries are intended 
to cover a wide chemotype space, we assessed the prevalence of py-
rimidines in the libraries. We found pyrimidines in 12 of the 411 frag-
ments in the UCSF libraries and in 72 of the 2122 XChem fragments 
(3.39% of the physically screened fragments) (fig. S5). Pyrimidines 
were found in 41,531 of the 722,963 (5.74%) in-stock fragments and 
in 890,199 molecules of the 20,006,175 compound fragment library 
(4.44%). While the percentages of molecules carrying the pyrimidine 
substructure were similar between the physical and docked fragments, 
the absolute numbers in the latter sets were far higher. Aside from 
bearing a pyrimidine substructure, these subsets were otherwise di-
verse: Among the 890,199 pyrimidine-containing docking fragments, 
60,919 distinct BM scaffolds were identified. Adenine itself was 
present in 5457 fragments (582 different scaffolds). Furthermore, as 
ADPr is negatively charged, anionic compounds were considered to 
exhibit favorable properties to bind to Mac1 by targeting the di-
phosphate region. Fortuitously, a substantial fraction (35%) of the 
UCSF fragment libraries is anionic (fig. S5).
Hit rates and Mac1 interaction sites of fragments
Across both crystal forms and facilities, we collected diffraction data 
for Mac1 crystals soaked with 2954 fragments (data file S1). The dif-
fraction characteristics of the P43 crystals were excellent: The aver-
age resolution was 1.1 Å, and 98% of the crystals diffracted beyond 
1.35 Å (Fig. 2, C and E, and fig. S2B). Although diffraction data were 
collected for 368 fragments soaked into the C2 crystals at UCSF, 
data pathologies meant that only 234 datasets could be analyzed. 
The datasets collected from C2 crystals had a mean resolution of 
1.4 Å and ranged from 1.0 to 2.2 Å (Fig. 2A and fig. S2B). In total, we 
identified 234 unique fragments binding to Mac1 using the PanDDA 
(pan-dataset density analysis) method (Fig. 2 and data files S1 and 
S2) (39). Of these, 221 were identified using P43 crystals (hit rate of 
8.8%) and 13 using C2 crystals (hit rate of 5.6%). Eighty percent of the 
fragments were identified in the Mac1 active site, near to or over-
lapping with the regions occupied by the nucleoside (the adenosine 
site) or the phosphoribose (the catalytic site) (Fig. 2G). Additional 
fragments were scattered across the surface of the enzyme, with an 
enrichment at a distal macrodomain-conserved pocket near lysine 
90 (the “K90 site,” 14 fragments) and with many others stabilized by 
crystal contacts (Fig. 2, B, D, and F, and fig. S6). Coordinates, struc-
ture factors, and PanDDA electron density maps for all the frag-
ments have been deposited in the PDB and are available through the 
Fragalysis webtool (https://fragalysis.diamond.ac.uk).
The unusually high hit rate for the adenosine site in the P43 form 
with the Enamine Essential library (21%) was in contrast to the rel-
atively low hit rate with this library with the C2 form (1.3%). Of the 
five pairs of fragments identified in both crystal forms, two pairs 
were identified in the adenine subsite in both crystal forms, two in 
the adenine subsite in P43 crystals but in the K90 site in C2 crystals, 
and the remaining pair bound to a surface site in the P43 crystals 
and in the K90 site in the C2 crystals (data file S1). Additional paired 
high-quality datasets were available for 54 fragments that were bound 
within the P43 crystals, but all showed no density for fragments in 
the C2 crystals (data file S1). It is possible that competition for bind-
ing with the N-terminal residues may have contributed to the rela-
tively low hit rate for the C2 form (fig. S3F).
Docking hits mimic the adenine recognition pattern
Docking the entire (20 million) ZINC15 fragment library, after cal-
ibration of docking parameters using different control calculations 
(see Materials and Methods) (37, 40), was completed in approximately 
5 hours of elapsed time on 500 cores. The 20,006,175 fragments were 
sampled in over 4.4 trillion complexes. Top-ranked molecules were 
inspected for their ability to form hydrogen bonds similar to ade-
nine (e.g., with the side chain of Asp22 and with the backbones of 
Ile23 and Phe156), while molecules with internal molecular strain or 
unsatisfied hydrogen bond donors were deprioritized. Ultimately, 
we selected 54 fragments from the entire ZINC15 fragment library 
screen, 9 of which were immediately available for purchase from 
Enamine and 33 of 45 make-on-demand molecules were successfully 
synthesized de novo. Furthermore, eight fragments were purchased 
from the ZINC15 in-stock fragment library screen, and an additional 
10 compounds were sourced on the basis of the in-human library 
docking (data file S1).
Of the 60 molecules tested for complex formation by crystal soak-
ing, 20 were observed with unambiguous electron density in complex 
with Mac1 (data file S1). Here too, the crystals diffracted to excep-
tionally high resolution, between 0.94 and 1.01 Å. The predicted 
docking poses typically superposed well on the observed crystallo-
graphic results [Hungarian method root mean square deviations 
(RMSDs) (41) ranging from 1 to 5 Å] and 19 of the 20 docking hits 
bound to the adenine subsite of Mac1, as targeted by docking (Fig. 3 
and fig. S7).
The most commonly observed scaffold among the docking hits 
was 7H-pyrrolo(2,3-d)pyrimidine occupying the adenine-binding 
subsite (Fig. 3, A  to C, and fig. S7, A and B). This ring system is 
typically hydrogen bonded with Asp22, Ile23, and Phe156. Fragments 
with this scaffold usually demonstrated high fidelity between the 
docking results and the high-resolution structures (RMSD, 1.5 to 
2.3 Å). For RMSD values of >2 Å, indicating noticeable deviations 
between docking and crystallography (42), visual inspection of docked 
and solved poses still revealed correct predictions of orientation and 
key interactions for most fragments in the targeted binding subsite 
(e.g., Fig. 3, C, F, and G). Different substituents can be attached to 
this headgroup, e.g., piperidine, adding a hydrophobic segment to 
the scaffold [e.g., ZINC336438345 (PDB 5RSE)], occupying most of 
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(A and B). In addition to hydrophobic variations, ZINC263392672 
(PDB 5RSG) attaches an anionic substituent to the pyrrolopyrimi-
dine scaffold, offering additional hydrogen bonds within the bind-
ing pocket (Fig. 3C). While docking predicted the carboxylic acid of 
compound ZINC263392672 to insert into the phosphate-binding 
tunnel, forming a hydrogen bond to Val49, the crystal structure in-
stead revealed hydrogen bonds to the backbone amines of Phe156 
and Asp157, which we defined as the “oxyanion” subsite within the 
adenosine site. Interactions with this backbone-defined oxyanion 
subsite were also observed for many other hits from both the dock-
ing and the crystallographically screened libraries (e.g., Fig. 3F and 
fig. S7E).
For a set of smaller, mainly adenine-like docking hits, modeled to 
only occupy the adenine subsite of the targeted adenosine-binding 
site (Fig. 3, D and E, and fig. S7, C and D), the comparison between 
docked and experimental poses revealed deviations between 1.3 and 
P43 at UCSF


































































97 24 59 5407 57
20 33 19 1760 2
13 5.6 10 1234 6
C2 at UCSF
180°

















































Fig. 2. Crystallographic screening identified 234 fragments bound to Mac1. (A, C, and E) Histograms showing the resolution of the crystallographic fragment screen-
ing data. The resolution of datasets where fragments were identified are shown with blue bars. (B, D, and F) Surface representation of Mac1 with fragments shown as 
sticks. (G) The Mac1 active site can be divided on the basis of the interactions made with ADPr. The “catalytic” site recognizes the distal ribose and phosphate portion of 
the ADPr and harbors the catalytic residue Asn40 (10). The “adenosine” site recognizes adenine and the proximal ribose. The number of fragments binding in each site is 
indicated. (H) Summary of the fragments screened by x-ray crystallography, including the number of BM scaffolds and anionic fragments identified as hits in each screen. 
“Processed datasets” refers to the number of datasets that were analyzed for fragment binding with PanDDA. Of the datasets collected for 2954 fragments, 211 (7.1%) 
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4 Å. Making these somewhat larger deviations harder to interpret 
was that, for several fragments, the crystallographically observed 
pose, e.g., ZINC331945 (RMSD, 3.97 Å; Fig. 3E) and ZINC763250 
(RMSD, 3.78 Å; fig. S7D), is partially stabilized by interactions with 
the symmetry mate (see below).
Another group of docking hits was selected for their close mim-
icry of the adenosine scaffold (Fig. 3, F and G, and fig. S7, I to L). For 
these, the ultrahigh resolution of the crystal structures was crucial, 
revealing that for four of these, the wrong purine isomer had been 
inadvertently synthesized, with alkyl derivatives from the N3 rather 
than the intended N9 nitrogen corresponding to the alkylation of 
adenine in ADPr (fig. S7, I to L). Characterization of the original 
compound samples by high-performance liquid chromatography–
mass spectrometry (HPLC-MS) and nuclear magnetic resonance con-
firmed that the delivered compounds were >95% pure, misassigned 
positional isomers. For ZINC901381520 (Fig. 3F), both N3 (PDB 
5RSK) and N9 (PDB 5S6W) isomers were synthesized in different 
batches and confirmed to bind to the targeted adenosine-binding 
site forming equal hydrogen bond interactions with the protein 
(fig. S7I). ZINC3888754 (PDB 5RSC) (Fig. 3G) contains an adenine- 
like heterocycle extended by methyl groups at the C7 and C8 posi-
tions, revealing opportunities for expanding purine scaffolds beyond 
the adenine subsite to achieve Mac1 selectivity over other adenine- 
binding proteins.
In addition to hydrogen bonding with residues involved in the 
adenine recognition of ADPr, several docking hits hydrogen bond 
to the backbone carbonyl group of Ala154 (Fig. 3, D and I, and fig. 
S7G), revealing an intriguing accessory polar contact within this 
subsite. While most residues surrounding the adenosine-binding 
site adopted similar conformations in the fragment-bound crystal 
structures, as in the ADPr-bound structure used for docking (PDB 
6W02) (34), Asp22 and Phe156 adopted multiple, alternative confor-
mations. In most fragment-bound crystal structures, Phe156 rotated 
by approximately 90°, enabling improved face-to-face p-p stacking 
against the aromatic moieties in the bound fragments (Fig. 3, C to G). 
However, the docking template orientation of Phe156 was retained 
for other pyrimidine-containing fragment-bound crystal structures 
(Fig. 3, B and H).
Fig. 3. Docking hits confirmed by high-resolution crystal structures. The protein structure (PDB 6W02) (34) prepared for virtual screens is shown in green, predicted 
binding poses are shown in blue, the crystal protein structures are shown in gray, and the solved fragment poses are shown in yellow, with alternative conformations 
shown in light pink. PanDDA event maps are shown as a blue mesh. Event maps were calculated before ligand modeling, and the maps are free from model bias toward 
any ligand (39). Protein-ligand hydrogen bonds predicted by docking or observed in crystal structures are colored light blue or black, respectively. Hungarian RMSD val-
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Overall, two characteristics stand out from the docking screen: 
First, despite some important differences, there was high fidelity be-
tween the docking-predicted poses and those observed by crystal-
lography. The docking hits explored the adenine subsite to which 
they were targeted. Second, these hits did so with relatively dense 
variations around several chemotypes, something afforded by the 
granularity of a >20 million–fragment library. This density can be 
explored further, for example, 9170 fragments (888 unique BM scaf-
folds) in the ZINC15 fragment library contained 7H-pyrrolo(2,3-d)
pyrimidines; the functional group repeatedly observed in crystallo-
graphically confirmed docking hits (Fig. 3, A to C).
Analysis of key interactions between Mac1 and fragments 
from the crystallographic screens
Fragments binding to the adenine subsite
While docking was successful in targeting the adenine-binding sub-
site, crystallographic fragment screening has the advantages of being 
binding site agnostic and has the potential to identify novel chemo-
types at multiple sites. In total, crystallographic screening identified 
99 fragments that form subsets of the three hydrogen bonds found 
between Mac1 and ADPr within the adenine subsite (Fig. 4, A to C). 
Fragments that formed at least two hydrogen bonds to the adenine 
subsite were separated into nine classes based on the number, na-
ture, and connectivity of atoms involved in this hydrogen bonding 
(Fig.  4D). The most common class consisted of a 1,3-hydrogen 
bond donor/acceptor motif (Fig. 4, D, E, and I). This resembles the 
kinase hinge–binding motif, with the difference being the engage-
ment of a side-chain oxygen rather than a backbone carbonyl oxy-
gen (fig. S8, A and B) (43). While 7 of 18 fragments in this class were 
4-amino-pyrimidine derivatives, other moieties were also found, 
including two 2-amino-thiazole–based fragments and several pu-
rine derivatives (data file S1). We also observed an unusual adenine- 
binding mode with a hydrogen bond formed between Ile23 and N7 
instead of N1 (Fig. 4, D and E, II). The alternative binding mode can 
be explained by the N3 substitution of adenine on this fragment, 
which prevents formation of the canonical N1-Ile23 hydrogen bond. 
This pattern of hydrogen bonds to the protein has not been previ-
ously observed in adenines linked through N9 (44).
We also observed diverse fragments without adenine-like motifs 
binding at this site, including succinimides, amides, thiazoles, di-
aminopyridines, pyrazoles, pyrroles, and ureas (Fig. 4, D and E, III 
to VIII). These exploited, separately and together, Asp22, Ile23, Ala154, 
and, occasionally, all three adenine-defining hydrogen-bonding 
residues. Several fragments p-p stacked with Phe156, while those 
bearing a urea hydrogen bonded with the carboxylate of Asp22 
(Fig. 4, D and E, VIII). These interactions were reproduced by a series 
of benzimidazole-based fragments (Fig. 4, D and E, IX). These classes 
occupied what might be classified as an “upper” subsite, above that 
defined by the adenine-ribose axis (Fig. 2G), and may provide an 
opportunity to grow fragments away from the canonical site.
Fragments binding to the oxyanion subsite
In total, we identified 54 fragments that formed interactions with an 
unexpected oxyanion subsite, defined by the backbone nitrogens of 
Phe156 and Asp157 adjacent to the adenine subsite (Figs. 2G and 5A). 
As suggested by its name, most of these fragments (48 of 54) were 
anionic (data file S1). The defining backbone nitrogens adopted a 
similar orientation to those defining the classic oxyanion hole of 
serine hydrolases such as acetylcholinesterase (fig. S8, D to F). In 
the Mac1-ADPr structure, the C2 hydroxyl (2′OH) of the proximal 
ribose interacts with the oxyanion subsite via a bridging water 
(Fig. 5A). In total, 54 fragments formed at least one hydrogen bond 
to the oxyanion subsite (Fig. 5B). Here too, the fragments were both 
geometrically (Fig. 5C) and chemically diverse (Fig. 5D): orienting 
groups either toward the phosphate tunnel, the lower site, or wrapped 
around toward the upper adenine subsite, providing multiple op-
portunities for further elaboration. Chemically, they interacted with 
the site using not only a carboxylate but also sulfones, as well as 
isoxazole, a-keto acid, and a succinimide (Fig. 5E). We suspect that 
the presence of the oxyanion subsite explains the higher hit rate for 
the Enamine Essential library versus the other crystallographic frag-
ment libraries screened (27% versus 6%), as the former had a greater 
proportion of acids than the others (41% versus 4%) (fig. S5).
Fragments binding to the catalytic and other potential 
allosteric sites
There were substantially fewer hits against the catalytic site (Fig. 2G) 
versus the adenosine site (8 versus >100), although both appear to 
be accessible (fig. S3B). The catalytic site consists of three subsites: 
the phosphate tunnel, which is occupied by the diphosphate of ADPr; 
the ribose subsite, which is occupied by the terminal ribose of the 
molecule; and the outer subsite, which sits between Asn40 and Asn99 
(Figs. 2G and 6A). Of the eight fragments binding in the catalytic 
site, seven bound in the outer subsite, and one bound in the phos-
phate tunnel. Binding to the outer site was often defined by hydro-
phobic packing between the Tyr42 and Lys102 side chains, although 
POB0135 (PDB 5S3W) and POB0128 (PDB 5S3T) formed a salt 
bridge to Lys102 (e.g., Fig. 6A, I). The latter fragment was also found to 
bind in the adenosine site. Other molecules, including Z2234920345 
(PDB 5S2L) and Z955123498 (PDB 5S4A) stabilize an alternative 
conformation of Lys102 (Fig. 6A, II). Three of the fragments, includ-
ing Z85956652 (PDB 5S2U), positioned a halogen atom in the outer 
subsite (e.g., Fig. 6A, III). The only fragment identified in the phos-
phate subsite was ZINC84843283 (PDB 5RVI). This fragment was 
wedged between the Gly47/Ile131 loops and increased the gap be-
tween the two loops by 1.6 Å (Fig. 6A, IV). The absence of frag-
ments binding to the ribose subsite, as well as the sparsity of 
fragments in the phosphate tunnel, means that designing a Mac1 
inhibitor to occupy the catalytic site will rely more heavily on frag-
ment growing than on fragment merging.
Both crystallographic screens also identified fragments binding 
to the K90 site, which is formed by a cleft between Lys31, Thr32, and 
Lys90 (Fig. 6B). We identified seven fragments from the C2 crystal 
form and six from the P43 crystal form; none of the C2-derived frag-
ments were found again when the UCSF libraries were rescreened 
under the P43 crystal condition. Although the K90 site is 15 Å from 
the adenosine site, it is connected to that subsite via a single a helix 
(Fig. 6B). Although there is no biochemical evidence for allosteric 
communication between these sites, the fragments provide starting 
points for designing chemical probes to test this possibility.
Fragment binding exploits protein conformational 
flexibility
To identify Mac1 flexibility associated with molecular recognition, 
we calculated the root mean square fluctuation (RMSF) of side-chain 
atoms across the P43 fragment-bound structures. Residues lining 
the adenosine site, especially Asp22 and Phe156, are the most flexible 
(Fig.  7,  A  and  B). The flexibility of both residues is paralleled in 
previously reported crystal structures (Fig. 7C) and also in the 0.77-Å 
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are clearly defined in electron density maps (Fig. 7D and fig. S1, A to C). 
In the ultrahigh-resolution structure, residues 155 to 159 are modeled 
as a combination of two distinct backbone conformations that diverge 
substantially at Phe156, which requires three distinct conformations 
of this residue to satisfy the observed density (Fig. 7D and fig. S1C). 
Despite this flexibility, hydrogen bonds to Asp22 are present in 
many fragments, including docking compounds that were chosen 
on the basis of interactions with a static receptor (Fig. 7E). Similarly, 
the flexibility of the aromatic side chain of Phe156 enables adaptable 
stacking interactions with fragments (Fig. 7, E and F), with 46 
fragments binding within 4 Å of Phe156. As with Asp22, the nature 
and geometry of these interactions are maintained for many soaked 
and docked fragments even as the residue moves relative to the rest 
of the protein.
In contrast to the adenosine site, little conformational heteroge-
neity is observed at the catalytic site, with only minimal changes in 
Lys102 and Tyr42 conformations (Fig.  7G). Still, even in this site, 
there is more conformational heterogeneity observed in previously 
published structures (Fig. 7H). In particular, a network of flexible 
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Fig. 4. Fragments binding to the adenine subsite. (A) Stick representation showing the interaction of the adenosine moiety of ADPr with Mac1. The key hydrogen 
bonds are shown as dashed lines. (B) Plot of the distances shown in (A) for all fragment hits. The distances, truncated to 10 Å, are for the closest noncarbon fragment atom. 
(C) Stick representation showing all fragments interacting with Asp22-N, Ile23-N, or Ala154-O. The surface is “sliced” down a plane passing through Asp22. (D) Structures of 
the nine unique motifs that make at least two hydrogen bonds to the adenine subsite. Colored circles match the interactions listed in (A) and (B). The number of fragments 
identified for each motif are listed in parentheses. (E) Examples of the nine structural motifs. The fragment is shown with yellow sticks and the PanDDA event map is 
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distinct conformation upon ADPr binding (Fig. 7I). To further 
probe the flexibility of the Phe132-Asn99-Lys102 network, we deter-
mined structures of Mac1 using the C2 crystal at human physiolog-
ical temperature (37°C, 310 K) to 1.5-Å resolution (Fig. 7J and data 
file S1). As observed in other systems (45, 46), we noticed that the 
cryogenic structure appeared more compact than the structure at 
higher temperatures. Specifically, we observed substantial loop dis-
placements near the ribose-binding pocket of the active site, which 
are coupled to a global hinge-bending motion involving correlated 
motion of helices about the central b sheet (fig. S4, F and G). The 
structure at physiological temperature more closely resembles the 
structure with ADPr bound, with the backbone adopting a more 
open conformation (Fig. 7J). However, the side-chain rotamers of 
Asn99 and Lys102 do not undergo the larger rearrangements. This 
temperature-dependent change in the width of the active site cleft 
can provide alternative, potentially more relevant, conformations 
for future ligand discovery efforts targeting the catalytic site around 
the distal ribose.
Changes in water networks upon fragment binding
To assess the role of water networks in fragment binding, we first 
examined changes in water networks upon ADPr binding. In the 
0.85-Å P43 apo structure, the catalytic site contains 14 water mole-
cules arranged in an ordered network that connects the Gly47 loop 
and the Ile131 loop, with an arc formed around the Phe132 side chain 
(Fig. 8A). In contrast, waters were more disordered in the adenosine 
site, with more diffuse electron density and higher B-factors (Fig. 8, 
A and C). Upon ADPr binding, five waters were displaced from the 
catalytic site, and the water network was disrupted (Fig. 8B). This 
disruption is partly caused by altered conformation of the Phe132 
and Asn99 side chains, which break the network between residues 



























































































Fig. 5. Fragments binding to the oxyanion subsite. (A) Stick representation showing the interaction of ADPr with the oxyanion subsite of Mac1. The water molecule 
bridging the ribose moiety and the oxyanion subsite is shown as a blue sphere. (B) Plot of the distances highlighted in (A) for all fragment hits. Distances were calculated 
as described for Fig. 4B. (C) Stick representation showing all fragments interacting with Phe156-N and Asp157-N. Fragments are colored by secondary binding site with blue 
as phosphate, black as lower, and yellow as adenine. The surface is sliced across a plane passing through Phe156 (white surface and gray interior). (D) Structures of the five 
structural motifs that bind the oxyanion site. (E) Examples of the five motifs. Three examples of motif I are shown, where the fragment also interacts with the phosphate, 
adenine, or lower subsite. The fragment is shown with yellow sticks, and the PanDDA event map is shown for reference as a blue mesh. ADPr is shown with transparent 
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stabilized in the Mac1-ADPr complex (Fig. 8B). The average B-factor 
decreased from 24 to 10 A2, and two networks connect the phos-
phate tunnel with the adenine/oxyanion subsites (Fig. 8C). Al-
though the adenine moiety only forms two direct hydrogen bonds 
to protein, it has four additional contacts via bridging water mole-
cules (Fig. 8B). Similar bridging waters were observed for frag-
ments binding in the adenosine site including ZINC340465 (PDB 
5RSV), which forms only one direct hydrogen bond to the protein 
but has an extensive hydrogen bond network via water molecules 
(Fig.  8D). Visualizing all water molecules within 3.5 Å of frag-
ment atoms shows clusters near protein hydrogen bond acceptors 
and donors (Fig. 8E). Of particular interest is the cluster near the 
backbone carbonyl of Ala154. This site is occupied by a water mole-
cule in the Mac1-ADPr structure and is bridged by adenine deriva-
tives such as ZINC340465 (PDB 5RSJ) (Fig. 8D). In addition, five 
fragments occupy this site directly (Fig. 4, A and D), including the 
C2-amino–substituted adenine present in ZINC89254160_N3 (PDB 
5RSJ; Fig. 3D). Extending fragments to displace the water molecules at 
other frequently populated sites could help to quantify the contribu-
tion of water networks to Mac1 binding and to provide a test set for 
computational methods that seek to exploit solvent dynamics for 
ligand optimization (47, 48).
Solution binding of fragment hits
To buttress the crystallographic studies, we biophysically screened 
selected compounds using DSF, ITC, and an HTRF ADPr-peptide 
displacement assay (Fig. 9 and data files S1 and S2). Because of their 
ready availability in useful amounts, most of these experiments fo-
cused on the docking hits. For DSF, in agreement with previous re-
ports for this enzyme (18), we observed substantial elevation of the 
apparent melting temperature (Tma) upon addition of ADPr (Fig. 9, 
C, D, and G). When tested in concentration response from 0.188 to 
3 mM, 10 of 54 docked fragments also induced small but statistical-
ly significant and dose-responsive Tma elevation (Fig. 9, C, D, and G, 
and data file S1). All 10 of these were also observed to bind in the 
crystallographic studies, providing relatively good agreement be-
tween these assays. However, the correlation was incomplete, as the 
remaining fragments observed by crystallography either decreased 
the Tma or had no significant effect (data file S1).
To identify fragments with the most promising binding affinity 
for optimization, we tested the 19 crystallographically observed 
docking hits using ITC (data files S1 and S2). Because of their small 
size, most of these fragments have low binding affinity and release 
little heat upon binding versus ADPr. Thus, we only observed reli-
able thermodynamic measurements for 4 of the 19 fragments. These 
could be fit to a single-site binding model with affinities in the low 
millimolar range (Fig. 9, E and G), consistent with the DSF results. 
Furthermore, the compounds measured by ITC that released the 
greatest amount of heat also induced significant Tma shifts in DSF 
(data file S1).
Last, we tested 57 docking-derived fragments and 18 crystallo-
graphic hits from the XChem library in an HTRF-based peptide 
displacement assay, which monitors displacement of a fluorescently 
labeled ADPr-conjugated peptide from the active site of Mac1 (Fig. 9, 
F and G, and data files S1 and S2). Eight of 57 docking hits (14%) 
and 3 of 18 crystallographic hits (17%) inhibited the enzyme with 
median inhibitory concentration (IC50) values between 180 mM and 
1 mM, with the most potent fragment being the docking-derived 
ZINC263392672 (PDB 5RSG) with an IC50 of 183 mM in this assay. 
Only 5 [ZINC3888754 (PDB 5RSC), ZINC331945 (PDB 5RSD), 
ZINC263392672 (PDB 5RSG), ZINC336438345 (PDB 5RSE), and 
ZINC6180281 (PDB 5RSF); Fig. 3] of the 10 docking hits that stabi-
lized Mac1 as measured by DSF were inhibitory in the ADPr-peptide 
displacement assay. Two docking hits that were not identified as 
binders by DSF or crystallography, ZINC1337772170 (IC50 = 971 mM) 
and pterin (IC50 = 784 mM), were found to be inhibitors in the pep-
tide displacement assay (Fig. 9H). This result might be explained by 
the use of a detergent in the peptide displacement assay that could 
increase compound solubility. With its ability to detect inhibition of 
Mac1, the ADPr-peptide displacement assay proved to be a sensi-
tive and complementary strategy for further characterization of the 
fragment hits obtained from the docking and crystallographic screens. 
Assuming that the HTRF-based peptide displacement assay pro-
duced the most reliable inhibition data, we estimated ligand effi-
ciencies from IC50 values for hits for which we obtained reasonable 
dose-response curves. ADPr, with an IC50 of 161 nM and 36 heavy 























POB0135 | 5S3W Z2234920345 | 5S2L













Fig. 6. Fragments targeting the catalytic and potential allosteric sites are 
sparsely populated compared to the adenosine site. (A) Surface representation 
showing fragments that bind near the catalytic site. The fragment POB0135 (PDB 
5S3W) bridges the gap between Asn40 and Lys102 via a hydrogen bond and a salt 
bridge, respectively. Although eight fragments bind in the outer subsite, the frag-
ment POB0135 makes the highest-quality interactions. No fragments bind in the 
ribose subsite. The fragment ZINC331715 (PDB 5RVI) inserts into the phosphate 
subsite between Ile131 and Gly47. (B) Left: The K90 site is connected to the adenosine 
site by the Asp22-Val30 a helix. Right: Surface representation showing two fragments 
that bind to the K90 site. Hydrogen bonds are shown as dashed black lines. The 
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docking hits ZINC3888754 (PDB 5RSC, LE = 0.26), ZINC336438345 
(PDB 5RSE, LE = 0.28), ZINC263392672 (PDB 5RSG, LE = 0.32), 
and ZINC331945 (PDB 5RSD, LE = 0.38) reveal similar or slightly 
improved ligand efficiencies, while the highest LE was calculated for 
the XChem library hit SF005 (PDB 5S4G; Fig. 9H), with 0.44 kcal/
mol per heavy atom.
In summary, all crystallographically confirmed docking hits were 
tested using three complementary in-solution binding techniques, 
DSF, ITC, and an HTRF-based peptide displacement assay (fig. S9 
and data file S1). ZINC336438345 (PDB 5RSE), ZINC331945 (PDB 
5RSD), ZINC263392672 (PDB 5RSG), and ZINC26180281 (PDB 
5RSF) were the only four fragment hits for which binding data 
could be obtained by all three techniques (Fig. 9). All of these frag-
ments have key hydrogen bonds in the adenine subsite and p-p 
stack with Phe156. Furthermore, ZINC263392672 (PDB 5RSG) in-
teracts via its carboxyl group with the oxyanion subsite of Mac1. 
Last, we note that crystallography, DSF, and ITC all monitor bind-
ing but do not measure function. The peptide displacement assay is 
thus of particular value for fragment characterization because it mea-
sures specific displacement of an analog of the natural Mac1 substrate.
Opportunities for fragment linking and merging to optimize 
Mac1 inhibitors
Typically, one might be reluctant to speculate on optimization from 
fragment structures alone, but the unusually large number of struc-
tures perhaps supports some cautious inference here. Before modi-
fying, linking, or merging fragments, it is important to consider the 












































































































Fig. 7. Experimentally observed conformational heterogeneity is sampled by various fragments. (A) Plots of side-chain RMSF for the 117 fragment structures from 
the UCSF screen using P43 crystals. (B) Stick representation showing all fragments (black sticks) within 3.5 Å of the Asp
22 carboxylate and 4 Å of the Phe156 ring (white 
sticks). (C) Structural heterogeneity in the previously reported Mac1 structures. (D) The Phe156 side chain is captured in three conformations in the C2 apo structure. Elec-
tron density maps (2mFO-DFC) are contoured at 0.5 s (blue surface) and 1 s (blue mesh). For reference, ADPr is shown with blue sticks. (E) Plots of side-chain RMSD for 
Asp22 and Phe156 from the Mac1 apo structure as a function of ligand-protein distance. Structures were aligned by their Ca atoms, before RMSDs were calculated for the 
Asp22 carboxylate and the Phe156 aromatic carbons. (F) Fragment binding exploits preexisting conformational heterogeneity in the Phe156 side chain. The apo structure 
is shown with dark transparent gray sticks in each panel, and the conformational changes are annotated with arrows. (G) Stick representation showing all fragments 
(black sticks) in the outer subsite of the catalytic site. (H) Conformational heterogeneity of residues in the catalytic site of the previously reported Mac1 crystal structures. 
(I) ADPr binding induces a coupled conformational change in the Phe132, Asn99, and Lys102 side chains, as well as a 2-Å shift in the Phe132 loop. Electron density maps 
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forms a bipartite-enclosed pocket with a symmetry mate (Fig. 10, 
A and B). In particular, 24 fragments only hydrogen bond to Lys11 
of the symmetry mate and not with any residues in the adenosine 
site, indicating that these molecules should not be considered for 
fragment elaboration (Fig. 10, C and D). On the basis of the binding 
poses of remaining compounds, fragment pairs were linked into hy-
pothetical scaffolds. These were used as templates to search the 
make-on-demand chemical space of the Enamine REAL database 
using the SmallWorld similarity (http://sw.docking.org) and Arthor 
substructure (http://arthor.docking.org) search engines (Fig. 10, 
E and F) (49). In a second approach, fragments with overlapping 
binding poses were merged into larger scaffolds, e.g., the purine of 
ZINC89254160_N3 (PDB 5RSJ) interacting in the adenine-binding 
subsite was replaced by ZINC26180281 (PDB 5RSF), adding an ad-
ditional hydrogen bond to Ala154 (Fig. 10F). Whereas it remains 
speculative whether the suggested linked or merged molecules are 
indeed active against Mac1, the scaffolds observed here, as well as 
the key interactions they make with the enzyme, indicate a fruitful 
chemical space to further explore. Naturally, many of the fragments 
described here also merit investigation by alternative fragment 
growing or analoging strategies.
DISCUSSION
Three key observations emerge from this study. Most noteworthy is the 
sheer number and the unusually high resolution of the 234 fragment- 
bound Mac1 structures, including 192 fragments identified in the 
active site. The fragments cover both stereotypical interactions 
(such as adenine-like hydrogen bonding to the Asp22 side chain/
Ile23 backbone and stacking interaction with Phe156) as well as di-
verse and unusual chemotypes that exploit active site flexibility (for 
instance, by targeting the oxyanion subsite). This abundance and 
diversity afford multiple starting points for future elaboration into 
lead-like molecules. Second, the high fidelity of docked poses to the 
subsequent crystallographic results supports the use of docking to 


























































Fig. 8. Water networks in the active site are displaced and used by fragments for bridging interactions. (A) Water networks in the apo enzyme (P43 crystal form). 
Waters are shown as blue spheres, with electron density contoured at 5.0 s (blue mesh) and 1.5 s (blue surface). Hydrogen bonds are shown as dashed lines (distances 
are 2.6 to 3 Å). (B) Water networks in the Mac1-ADPr complex. ADPr is shown as cyan sticks. Conformational changes upon ADPr binding are highlighted with black arrows. 
(C) Comparison of crystallographic B-factors of water molecules in the catalytic site and adenosine site. The range and 95% confidence interval are shown. (D) Examples 
of the role of water networks in fragment binding. Left: ZINC340465 (PDB 5RSV) forms a single hydrogen bond to the protein (green dashed line) but forms five hydrogen 
bonds via water molecules. Right: Although few fragments of hydrogen bond directly to the backbone oxygen of Ala154, several fragments interact with this residue via 
bridging water molecules (red dashed line) including ZINC89254160_N3 (PDB 5RSJ). (E) Plot showing all water molecules that lie within 3.5 Å of a noncarbon fragment atom. 
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IC50 =  
370 ± 30 µM
 IC50 =  
880 ± 30 µM
IC50 =  
570 ± 40 µM
IC50 =  
970 ± 50 µM
Fig. 9. Biophysical corroboration of solution binding of crystallographic fragment hits by DSF, ITC, and ADPr-peptide displacement assay. Top: (A to F) Perfor-
mance of the most potent fragment hits in DSF, ITC, and ADPr-peptide displacement assay compared to ADPr. (C) Normalized raw DSF relative fluorescence unit (RFU) 
data demonstrate canonical unfolding curves and minimal compound-associated curve shape aberrations. Gradient color scales, 0 mM (yellow) and 3 mM (purple). 
(D) Tma elevation reveals Mac1 stabilization through fragment binding. Data points represent the means ± SD for triplicate measurements at each compound concentra-
tion. (E) Integrated heat peaks measured by ITC as a function of compound:protein molar ratio. The black line represents a nonlinear fit using a single-site binding model. 
(F) Peptide displacement assay measures ADPr-peptide displacement (i.e., % competition) from Mac1 by ligand. Data points represent the means ± SD for duplicate 
measurements at each compound concentration, and the black line represents a nonlinear fit using a sigmoidal dose-response equation constrained to 0 and 100% 
competition. (G) Summary of solution binding data for fragments from top panels. DTma values are given for the highest compound concentration in this assay 
(means ± SD). For the ITC and peptide displacement experiments, parameters obtained by nonlinear regression are given (±estimated SE). (H) Additional fragment hits 
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docking to prioritize fragments, at least for this target, something 
still debated in the field. Last, with 234 diverse fragment structures 
determined, it should be possible to exploit the fortuitous juxtapo-
sition of fragment pairs to design joined ligands that combine the 
affinities of both, leading to inhibitors with the low micromolar af-
finity needed for hit-to-lead optimization. One clear strategy in-
volves extending molecules bound to the adenine subsite and with 
biophysically measurable binding affinities into the phosphate and 
distal ribose recognition regions.
In contrast to the large number of chemically diverse hits bind-
ing to the adenine subsite, the lack of fragments bound to the cata-
lytic site is notable and may inform models of how ADP-ribosylated 
peptides bind to Mac1. The paucity of fragments is especially un-
usual given that three crystal environments (the A and B chains in 
the P43 crystal and the C2 crystal) were screened and that the site 
appears accessible in all lattices (fig. S2B). The two major models for 
peptide-macrodomain interactions are either that the peptide binds 
along the widened cleft defined by Tyr42 and Lys102 or that it extends 
into solution through the flexible Gly46–48 loop (50). We observe frag-
ments that bind in both locations (Fig. 6A). Regardless of the binding 
mode, which could be distinct depending on the identity of the mod-
ified residue and target substrate, the lack of binding at this site sug-
gests that the binding energy comes mostly from the ADPr and not 
from the amino acids on the ADPr-conjugated protein. This hypoth-
esis is also supported by the fact that Mac1 can hydrolyse a wide range 
of ADP-ribosylated substrates (2, 51). Docking of larger “lead-like” 
molecules, perhaps enabled by the expanded catalytic site revealed by 
the physiological temperature structure and detailed description of 
solvent, may help to identify molecules exploiting this site.
The success of the fragment docking campaign contrasts, perhaps, 
with expectations of the field that fragments have too few functional 
group handles to accurately dock or prioritize (52). Not only were 
hit rates high (33%) but also was the fidelity of most docking poses 
to the crystallographic results. Even judged by potency, the most 
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Fig. 10. Fragments bridging multiple adenosine sites provide direct merging opportunities. (A) Sliced view of the adenosine site (white surface and gray interior) 
and a symmetry mate (blue surface and interior) showing the deep pocket created by crystal packing in the P43 crystals. The 66 fragments that hydrogen bond with the 
Lys11 backbone nitrogen are shown as sticks. (B) Plot showing distances between the symmetry mate (Lys11-N) and the adenine subsite (Asp22-Od, Ile23-N, and Ala154-O) 
for all fragments identified in the adenosine site. Dotted lines show the 3.5-Å cutoff used to classify hydrogen bonds. (C) An example showing 1 of the 24 fragments that 
bound in the adenosine site, yet only formed a hydrogen bond with the symmetry mate. (D) An example of one of the fragments that bridged the 9- to 11-Å gap between 
the adenine subsite and the symmetry mate. (E and F) Opportunities for fragment linking and merging. Adjacent or overlapping fragments were initially merged into a 
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active fragment to emerge from this study, the 183 mM inhibitor 
ZINC263392672 (PDB 5RSG) (Figs. 3 and 9), was a docking hit. In 
addition, it was the docking hits that were most readily available for 
this functional testing, as they were sourced in 10 mg amounts, 
while the crystallographic screening compounds were often in short 
supply. This is a purely mechanical advantage of docking, and it is 
counterbalanced by the small numbers tested versus the crystallo-
graphic screens; still, having substantial material to work with is a 
pragmatic advantage. Admittedly, weaknesses also emerged from 
the docking. The oxyanion site that featured so prominently among 
the crystallographic screening hits was not to be found among the 
docking predictions. This gap reflects both a failure of the docking 
scoring function to prioritize anions binding to this site (as they were 
at least sampled) and, to some extent, a failure of the docking group 
to pick the few molecules that did dock well to this site as likely can-
didates. More broadly, as we docked against a single rigid structure 
of the protein, the subsequent conformational changes that the pro-
tein underwent, as well as the changes in the water network, were 
not captured in the docking predictions, and this was sometimes 
reflected in the larger RMSD differences between predicted and ob-
served fragment poses (Fig. 3). These caveats, important as they are, 
should not obscure a central observation from this study: The dock-
ing hit rate was not only high, but the hits were also typically right 
for the right reasons; this may be something to build on for the field.
From the docked compounds, the most promising hits identified 
by in-solution binding experiments were also crystallographically 
confirmed. However, as expected, most hits from crystallography 
did not show appreciable activity in the orthogonal biophysical as-
says within the tested concentration range (up to 10 mM in ITC; 
data file S1). The macrodomain ADPr-peptide displacement assay 
also identified two docking hits not previously observed in soaking 
(ZINC1337772170 and pterin), which suggests that the crystal envi-
ronment limited the ability of some fragments to bind. However, 
between solution experiments, good consensus was observed for 
ZINC263392672 (PDB 5RSG), ZINC336438345 (PDB 5RSE), and 
ZINC331945 (PDB 5RSD). While we are aware that obtaining high- 
quality binding data remains particularly challenging for weak 
binders such as fragments, the dose-response results obtained in the 
complementary assays for many of the identified hits provided con-
vincing evidence for their true binding to Mac1. The inconsistency 
of fragment binding to different crystal systems of the same protein 
is apparent when comparing fragments that resulted in high-quality 
datasets in both the P43 and C2 crystal systems. Unexpectedly, only 
5 of 59 possible fragments were observed in both systems, with 
3 fragments binding with equivalent poses in the adenine subsite. This 
observation points to the value of having multiple measurements, 
and even multiple crystal systems when they are available, in 
fragment-based drug discovery approaches.
Overall, this study has three main implications for the discovery 
of SARS-CoV-2 Nsp3 Mac1 inhibitors and for antiviral efforts 
targeting macrodomains more broadly. First, we not only describe 
new chemical matter for this target but also map its hotspots at 
high resolution. This provides a template for future inhibitor dis-
covery and development against this enzyme. These efforts will need 
to navigate selectivity over human macrodomains and other ade-
nosine triphosphate–binding proteins including kinases (fig. S8, A 
to C) and consider breadth across other viral macrodomains (fig. S4, 
I and J) (12). Second, the specific fragments that we describe may 
lend themselves directly to optimization: Several examples are 
discussed explicitly, amenable to make-on-demand chemistry (Fig. 10, 
E  and  F), and the 234 structures should provide inspiration for 
countless other molecules. Last, important technical advances emerged 
from this study: a crystal form that lends itself to ready structure deter-
mination, the creation of a reliable peptide displacement assay for 
Mac1, and evidence supporting the ability of structure-based screen-
ing, such as molecular docking, to predict effective fragments. The 
ultrahigh-resolution x-ray diffraction data, which allowed hydrogen 
atoms to be refined explicitly, as well as electron density to be re-
solved on a subatomic scale, make Mac1 an attractive candidate for 
in-depth computational dissection of its catalytic mechanism using 
approaches that integrate both classical and quantum calculations. 
Together, these advances will speed progress throughout the com-
munity to help validate this target and create effective antivirals.
MATERIALS AND METHODS
Fragment libraries
We screened 2122 molecules from the XChem facility at Diamond 
Light Source against the Mac1 P43 crystal form and 411 molecules 
from UCSF against the C2 and P43 crystal forms (data file S1). The 
fragment library at XChem combined molecules from multiple frag-
ment libraries: the Diamond Light Source, SGC, and iNEXT (DSI)–
poised library [687 molecules (36)], the Edelris fragment collection 
(132 molecules), the MiniFrags Probing Library [80 molecules (53)], 
the FragLites collection [31 compounds (54)], the PepLite library 
[22 molecules (26)], the SpotFinder library (96 compounds), the 
York3D library [106 molecules (55)], and the EU-OPENSCREEN 
(968 molecules). The UCSF fragment library was composed of 
Enamine’s Essential Fragment library (320 compounds) and 91 ad-
ditional com pounds from an in-house library (UCSF_91). To assemble 
the UCSF_91 library, we selected topologically diverse molecules 
having more than 10,000 commercially available analogs in at least 
three points of substitution, allowing for rapid and extensive analog 
by catalog without having to resort to flask synthesis. We picked 
molecules that were also BM scaffolds (38), stripped of acyclic ter-
minal substituents. We thought simple, unsubstituted frameworks 
would be easier to optimize by adding chemical matter during 
analoging. From among these, we prioritized by eye scaffolds with 
various ring sizes and combinations including fused rings, spiro sys-
tems, with linkers of varying lengths between rings, in an attempt to 
sample a diverse range of compact shapes and properties. We added 
anions where the anionic moiety was a small acyclic substituent on 
the scaffold, again picking by eye for shape diversity. We chose mol-
ecules with 11 to 21 heavy atoms, with molecular weights between 
200 and 300 amu and with a logP < 2.5 for solubility. Physical prop-
erties of all screened libraries are shown in fig. S5.
Analyses of scaffolds and specific chemotypes in the used chemical 
libraries are shown in fig. S5E. BM scaffold analysis was performed 
with the Molinspiration mib engine (www.molinspiration.com). Py-
rimidines were identified using RDKit (www.rdkit.org), and molecu-
lar charges at pH 7.4 were approximated using ChemAxon JChem 
version 2019.15 (www.chemaxon.com) to identify anionic fragments.
C2 crystals at UCSF
Protein expression and purification
SARS-CoV-2 Nsp3 Mac1 (residues 2 to 170) was cloned into a 
pET22b(+) expression vector with an N-terminal His6 tag and a 
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the tag (GenScript). In addition, a short linker (Asn-Ala-Gly) was 
included between the TEV recognition site and the Mac1 gene (data 
file S1). To express Mac1, plasmid DNA was transformed into BL21(DE3) 
Escherichia coli. After overnight growth on lysogeny broth (LB) 
agar supplemented with carbenicillin (100 mg/ml), starter cultures 
(10 ml of LB) were grown at 37°C for 8 hours. Large-scale cultures 
[1 liter of terrific broth] were grown at 37°C until an optical density of 
0.8. Cultures were cooled at 4°C for 15 min, before protein expression 
was induced with 1 mM isopropyl b-D-1-thiogalactopyranoside 
(IPTG), and the cultures were shaken at 20°C for 12 hours. Cells 
were collected by centrifugation and frozen at −80°C.
All purification steps were performed at 4°C using an AKTA fast 
protein liquid chromatography system (Cytiva). Cells were resus-
pended in Ni–nitrilotriacetic acid (NTA) binding buffer [50 mM 
tris-HCl (pH 8.0), 500 mM NaCl, 10 mM imidazole, 5% glycerol, 
and 2 mM b-mercaptoethanol (bME) supplemented with Turbo-
Nuclease (5 U/ml; Sigma-Aldrich, T4330)] and lysed by sonication. 
Cell debris was collected by centrifugation, and the lysate was ap-
plied to a 5-ml HisTrap HP column (Cytiva, 17524802). The col-
umn was washed with 25 ml of binding buffer followed by 25 ml of 
5% Ni-NTA elution buffer [50 mM tris-HCl (pH 8.0), 500 mM NaCl, 
500 mM imidazole, 5% glycerol, and 2 mM bME] and then eluted 
with 100% elution buffer. Eluted protein was exchanged into TEV 
reaction buffer [50 mM tris (pH 8.0), 100 mM NaCl, 1 mM dithio-
threitol (DTT), and 1% glycerol] using a HiPrep 26/10 desalting col-
umn (Cytiva, 17508701). To cleave the His6 tag, Mac1 was diluted 
to 1.5 mg/ml using TEV reaction buffer and incubated with recom-
binant TEV protease (56) at a 1:20 ratio (Mac1:TEV) for 16 hours at 
4°C. Cleaved Mac1 was separated from the uncleaved protein and 
TEV protease by rerunning the sample over a HisTrap HP column 
(pre-equilibrated with TEV reaction buffer) and collecting the flow-
through. The flow-through was supplemented with 10 mM DTT 
and concentrated to 2.5 ml using a 10-kDa molecular weight cutoff 
(MWCO) centrifugal concentrator (Amicon, UFC901024). The sam-
ple was further purified by size exclusion chromatography (SEC) 
using a HiLoad 16/600 Superdex 75 pg column (Cytiva, 28989333) 
equilibrated with SEC buffer [20 mM tris (pH 8.0), 150 mM NaCl, 
5% glycerol, and 2 mM DTT]. Eluted fractions were concentrated to 
15 mg/ml, flash-frozen in liquid nitrogen, and stored at −80°C. Pro-
tein used for ITC was purified in the same manner, but the SEC was 
run with 150 mM NaCl and 20 mM tris (pH 8.0). Protein was con-
centrated to 10.8 mg/ml before flash-freezing in liquid nitrogen and 
storage at −80°C.
Crystallization
Crystals were grown at 19°C using sitting-drop vapor diffusion with a 
reservoir solution containing 100 mM tris (pH 8.5), 100 mM sodium 
acetate, and 28% polyethylene glycol, molecular weight 4000 (PEG-
4000). Crystallization drops were set up with 200 nl of protein and 200 nl 
of reservoir. Initially, crystals were grown in MRC two-well plates 
(SWISSCI, MRC96TUVP) with a reservoir volume of 40 ml. Crystals 
grew to a maximum size after 1 to 2 days and were vitrified in liquid 
nitrogen without additional cryoprotection. For diffraction experi-
ments at physiological temperatures, crystals were mounted using 
ALS-style goniometer bases (MiTeGen, GB-B3S) and sealed with plas-
tic capillary and vacuum grease (MiTeGen, RT-T1). The capillary con-
tained 4 ml of reservoir solution to prevent crystal dehydration.
Fragment soaking was performed using crystals grown with 
SWISSCI three-well plates (SWISSCI, 3W96T-UVP). Microseeding 
was required to achieve consistent nucleation. Several large crystals 
grown in 100 mM tris (pH 8.5), 100 mM sodium acetate, and 28% 
PEG-4000 were transferred to a drop containing 5 ml of seed storage 
buffer [100 mM tris (pH 8.5), 100 mM sodium acetate, 32% PEG-
4000, and 2 mM DTT] on a silicon coverslip (Hampton Research, 
HR3-233). Crystals were crushed using a flattened glass rod and 
transferred to 200 ml of seed storage buffer, before being serially diluted 
1:10 with seed storage buffer. Consistent nucleation was achieved 
with seeds at a 1:100 dilution, with crystallization drops containing 
200 nl of reservoir, 100 nl of seed stock, and 300 nl of protein with 
30 ml in each reservoir.
Crystal dehydration and fragment soaking
Fragments were added to crystallization drops using acoustic dis-
pensing with an Echo 650 liquid handler (Labcyte) (23). Two librar-
ies were soaked at UCSF: the Enamine Essential fragment library 
(Enamine, 320 fragments) and the UCSF_91 library (91 fragments) 
(data file S1). To limit DMSO-induced crystal damage, fragments 
were targeted to crystallization drops as far away from crystals as 
possible (23). Initial DMSO tolerance tests indicated that the C2 
crystals were sensitive, rapidly disintegrating upon soaking with 
10% DMSO (fig. S2B). To enhance DMSO tolerance, 300 nl of a 
solution containing 35% PEG-4000, 100 mM tris (pH 8.5), and 100 mM 
sodium acetate was added to drops containing crystals using the 
Echo. Plates were resealed and incubated at 19°C for 6 hours. Frag-
ment solutions (120 nl, 10% of the drop volume) were added using 
the Echo, and plates were resealed and incubated at 20°C for 3 to 
8 hours. Crystals were vitrified directly from crystallization drops 
without additional cryoprotection.
Lysine methylation
Lysine methylation is a routine strategy for altering the crystalliza-
tion properties of a protein (35). All reagents were added with the 
protein on ice, and incubation steps were performed at 4°C with 
gentle shaking. First, 20  mg of Mac1 was exchanged into lysine 
methylation buffer [50 mM Hepes (pH 7.5), 150 mM NaCl, and 5% 
glycerol] using a HiPrep 26/10 desalting column. The protein was 
diluted to 1 mg/ml with lysine methylation buffer, and 400 ml of 1 M 
dimethylamine borane (DMAB; prepared in water) (Sigma-Aldrich, 
180238) and 800 ml of 1 M formaldehyde (prepared in water) (Sigma- 
Aldrich, F8775) were added to initiate the methylation reaction. 
The reaction was left to proceed for 2 hours, and then 400 ml of 1 M 
DMAB and 800 ml of 1 M formaldehyde were added. After an addi-
tional 2 hours, 200 ml of 1 M DMAB was added, and the reaction 
was left for further 16 hours. To consume any remaining formalde-
hyde and to cleave any intermolecular disulfide bonds, 2.5  ml of 
1 M glycine (prepared in water) and 2.5 ml of 50 mM DTT (pre-
pared in water) were added, and the reaction was incubated for an 
additional 2 hours. Next, the sample was concentrated to 2.5 ml using 
a 10-kDa MWCO concentrator and purified by SEC. The methylated 
protein was concentrated to 15 mg/ml before flash-freezing in liquid 
nitrogen and storage at −80°C.
To test the extent of lysine methylation, the purified sample was 
analyzed by LC-MS, using a Waters Acquity LC connected to a Waters 
TQ detector with electrospray ionization. The sample was separated 
on a C4 column held at 40°C using water with 0.1% formic acid as 
solvent A and acetonitrile with 0.1% formic acid as solvent B. After 
sample injection [5 ml at 10 mM diluted in 150 mM NaCl and 20 mM 
tris (pH 8.0)], an isocratic elution was run with 95% solvent A and 
5% solvent B for 1.5 min. Then, a linear gradient elution was run 
for 6.5 min to 95% solvent B. Last, an isocratic elution was run with 
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Crystallization of methylated Mac1
Crystals grew readily under the same conditions as the nonmethyl-
ated protein [100 mM tris (pH 8.5), 100 mM sodium acetate, and 
28% PEG-4000]. Consistent nucleation was achieved using micro-
seeding with the same protocol as the nonmethylated protein. Crys-
tallization drops were set up with 100 nl of reservoir, 100 nl of seed 
stocks, and 200 nl of protein using SWISSCI three-well plates. The 
methylated crystals displayed increased DMSO tolerance, so DMSO/
fragment soaks were performed directly with 40 nl of DMSO (10% 
of the drop volume).
Ultrahigh-resolution data collection, refinement, and modeling
To measure the diffraction at such high resolution, we used a multi-
pass, multicrystal data collection strategy. We collected ultrahigh- 
resolution x-ray diffraction data for Mac1 (C2 crystal form) by 
performing sequential high-energy (17,000 eV) and low-energy 
(11,111 eV) runs to accurately measure reflection intensities at high 
and low scattering angles, respectively. The same data collection 
strategy (wedge, oscillation angle, and exposure) was implemented 
for multiple crystals, each held in different orientations relative to 
the x-ray beam and phi rotation axis.
The datasets were individually indexed and integrated with 
XDS (57). During data processing, we merged the high- and low- 
resolution datasets from multiple crystals in different orientations 
to maximize our coverage of reciprocal space given a square de-
tector surface. A low-resolution cutoff of 2.5 Å was applied to the 
high-resolution (high-energy) datasets because this cutoff simulta-
neously excludes potentially overlapping reflections at low scattering 
angles and allows for a large number of shared observations be-
tween high- and low-resolution datasets, which facilitates robust 
scaling. Scaling and merging were performed using XSCALE, and 
the merged intensities were converted to structure factor magnitudes 
using XDSCONV (57).
We calculated phases by the method of molecular replacement, 
using the program Phaser (58) and a previous structure of Mac1 
(PDB 6WCF) as the search model. The model was manually adjusted 
in Coot (59) to fit the electron density map calculated from molec-
ular replacement, followed by automated refinement of coordi-
nates, atomic displacement parameters, and occupancies using 
phenix.refine (60) with optimization of restraint weights. Following 
two initial rounds of iterative model building and refinement using 
the aforementioned strategy, we began introducing additional pa-
rameters into the model, enabled by the extraordinarily high resolu-
tion of our diffraction data. First, we implemented anisotropic 
atomic displacement parameters for heavy atoms (C, N, O, and S), 
followed by refinement of explicit hydrogen atom positions. During 
early rounds of model building, we noticed mFO-DFC difference 
density peaks appearing between heavy-atom positions, suggesting 
that we are able to resolve covalent bonding densities (fig. S1E). 
Atomic refinement that included a model for interatomic scatter-
ers (IASs) (61) was able to account for these densities and reduce 
the free R value by approximately 0.0043 (0.43%). Although the 
refined atomic coordinates do not differ substantially based on 
the inclusion or exclusion of IASs, the maximum likelihood esti-
mation of the phase error calculated by phenix.refine is 0.49° 
less when the IASs are included, suggesting an improvement in 
map quality (which may indirectly improve the model by aiding 
in subsequent manual interpretation of electron density features). 
Final refinement was performed without geometry or ADP weights 
(unrestrained).
Data collection at physiological temperature, refinement, 
and modeling
We used a low-dose x-ray data collection strategy to acquire diffrac-
tion data from macrodomain crystals (C2 crystal form) at human 
physiological temperature (37°C, 310 K), which is the temperature 
most relevant to studies of SARS-CoV-2 infection. Using this strat-
egy, we acquired datasets using an x-ray exposure of only 50 kGy, 
less than 1% of the total dose used at 100 K, which is essential to 
mitigate the rapid rate of radiation damage at 310 K compared to 
100 K. The lower overall x-ray dose resulted in data with a lower 
overall resolution, extending to 1.5 Å.
Diffraction data from multiple crystals were merged using xia2 
(62), implementing DIALS (63) for indexing and integration, and 
Aimless (64) for scaling and merging. We calculated phases by the 
method of molecular replacement, using the program Phaser (58) 
and our high-resolution 100K structure as the search model. The 
model was manually adjusted in Coot to fit the electron density map 
calculated from molecular replacement, followed by automated refine-
ment of coordinates, atomic displacement parameters, and occupancies 
using phenix.refine (60) with optimization of restraint weights.
Fragment data collection, refinement, and modeling
Diffraction data were collected at ALS beamline 8.3.1 and SSRL 
beamlines 12-1 and 12-2. The data collection strategy is summa-
rized in data file S1. Fragment datasets were indexed, integrated, 
and scaled using XDS (57) run through xia2 (62). On the basis of the 
space group and unit cell dimensions, six crystal forms were present 
(fig. S2C). For each of the three C2 isoforms with one molecule in 
the ASU (isoforms A, B, and C), a single, high-resolution dataset was 
selected to create a representative model for each isoform. Phases 
were obtained via molecular replacement with Phaser (58), using 
the ultrahigh-resolution C2 coordinates as the search model (PDB 
7KR0). Coordinates were refined with iterative rounds of manual 
model building in Coot and refinement with phenix.refine (60). De-
fault refinement parameters were used, except the fact that five re-
finement macrocycles were carried out per iteration and water 
molecules were automatically added to peaks in the 2mFO-DFC 
electron density map higher than 3.5 s. The minimum model-water 
distance was set to 1.8 Å, and a maximum model-water distance was 
set to 6 Å. For later rounds of refinement, hydrogens were added to 
riding positions using phenix.ready_set, and B-factors were refined 
anisotropically for nonhydrogen and nonwater atoms. Although 
these datasets were obtained from crystals soaked with fragments, 
there was no evidence for fragment binding in the mFO-DFC differ-
ence density maps; therefore, the datasets were deemed acceptable 
as representative DMSO-only models for each isoform.
For the fragment datasets, molecular replacement was performed 
with Phaser (58) and initial refinement with Refmac (65), both run 
through the DIMPLE pipeline (66). The search model used for mo-
lecular replacement was selected to match the isoform of the dataset. 
Waters were included in the initial refinement by changing the HOH 
records in the PDB file to WWW. After refinement, waters were 
stripped from models, and electron density maps were analyzed for 
fragment binding using PanDDA (39). Electron density maps from 
31 datasets were used to calculate the background electron density 
map for the isoform A, and 24 datasets were used for isoforms B and 
C (data file S1). Datasets selected for background map calculation 
had the highest resolution and lowest Rfree values. After PanDDA was 
run with default parameters, the threshold used to classify a hit was 
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min_blob_volume = 5, min_blob_z_peak = 2.5). Although there was 
a substantial increase in false positives, the decreased threshold al-
lowed an additional seven fragments to be identified. Fragments 
were modeled into PanDDA event maps with Coot, using restraints 
generated by phenix.elbow from a SMILES (simplified molecular- 
input line-entry system) string (67). Changes in protein conformation 
and solvation were also modeled. Because PanDDA can identify 
fragments binding with low occupancies, any changes in protein coor-
dinates will have similar, low occupancies. If unrestrained refinement 
is performed on these low-occupancy models, then changes supported 
by PanDDA event maps are often reverted to the ground-state model. 
In the past, this has been overcome by refining both ground-state 
(apo) and changed-state (fragment bound) structures simultaneously, 
with the changed state coordinates restrained. However, these multi-
state models can be difficult to interpret. As an alternative, we modeled 
and refined the changed state only. To prevent reversion of the model 
into ground-state density, coordinate refinement was switched off 
after fragments were modeled. Hydrogens were added with phenix.
ready_set, waters were updated automatically, and B-factors were 
refined anisotropically for nonhydrogen and nonwater atoms. After 
one round of refinement, waters added into ground-state electron 
density were removed. This was achieved by aligning the DMSO-only 
model to the refined model and removing any water molecules within 
2.2 Å of the DMSO-only model. A final round of refinement was 
performed without updating water molecules.
P43 crystals at UCSF
Protein expression and purification
The C2 sequence in pET22b(+) was converted into the P43 sequence 
by removal of Glu170 and replacement of the N-terminal Asn-Ala-
Gly-Glu motif with a methionine. In addition, a Ser-Ser-Gly-Val-
Asp-Leu-Gly-Thr linker was introduced between the His6 tag and 
the TEV recognition sequence (data file S1). All cloning steps were 
performed by polymerase chain reaction (PCR) with overlapping 
primers and Gibson assembly (68). Protein was purified using 
the same protocol as the C2 protein, except that after SEC, the pro-
tein was concentrated to 40 mg/ml before flash-freezing in liq-
uid nitrogen.
Crystallization
Initially, crystals were grown by hanging-drop vapor diffusion with 
a reservoir solution containing 34% PEG-3000 and 100 mM N- 
cyclohexyl-2-aminoethanesulfonic acid (CHES) (pH 9.5). Screens 
were performed using pregreased VDX plates (Hampton Research, 
HR3-142) with 0.5 ml of reservoir solution in each well. Crystalliza-
tion drops were set up on silicon coverslips (Hampton Research, 
HR3-233) with 2 ml of Mac1 at 10 mg/ml and 2 ml of reservoir. Crystals 
grew after 2 to 4 days at 19°C. As with the C2 crystals, microseeding 
was required to achieve consistent nucleation. Seed stocks were pre-
pared as described previously, except the seed storage buffer used 
was 35% PEG-3000, 100 mM CHES (pH 9.5), and 2 mM DTT. Crystals 
for fragment soaking were grown using SWISSCI three-well sitting 
drop plates with reservoirs containing 30 ml of 28% PEG-3000 and 
100 mM CHES (pH 9.5). Crystallization drops were set up with 100 nl 
of reservoir solution, 100 nl of seed stocks (1:100,000 dilution), and 
200 nl of Mac1 at 40 mg/ml. Crystals were grown at 19°C and 
reached a maximum size after 24 hours.
Fragment and ADPr soaking
Fragment soaks were performed using the same protocol as the C2 
crystals, with soak times between 2 and 6 hours. ADPr soaks were 
performed similarly, except that ADPr was prepared in water to 100 mM, 
and crystals were soaked with 80 nl of ADPr (20 mM final concen-
tration). Crystals were vitrified directly after soaking using a NANUQ 
cryocooling device (MiTeGen).
Fragment data collection, processing, modeling, 
and refinement
Diffraction data were collected at ALS beamline 8.3.1, SSRL beam-
line 12-1, and NSLS-II beamline 17-ID-2. The data collection strat-
egy is summarized in data file S1. Fragment datasets were indexed, 
integrated, and scaled using XDS (57) and merged with Aimless 
(64). In addition to the fragment soaks, we collected diffraction data 
for 40 crystals soaked only with DMSO. To generate a DMSO-only 
model, a single high-resolution dataset was selected, and phases 
were obtained by molecular replacement using the 0.77-Å C2 struc-
ture as a search model (PDB 7KR0). Refinement and model build-
ing were performed as described previously for the C2 crystals. The 
fragment datasets were prepared for PanDDA analysis using the 
DIMPLE pipeline (39, 66). Fragments were identified using PanDDA, 
with the background electron density map generated using 35 
DMSO-only datasets. As with the analysis of C2 electron density maps, 
PanDDA was rerun with a decreased Z-map threshold (contour_
level = 2.5, min_blob_volume = 5, min_blob_z_peak = 2.5). This 
strategy identified an additional 24 fragments. Fragment modeling 
and refinement were carried out using the same protocol as the 
experiment with C2 crystals.
P43 crystals at Oxford/XChem
Protein expression and purification
SARS-CoV-2 Nsp3 Mac1 (residues 3 to 169) was cloned into a 
pNIC28-Bsa4 expression vector, which adds an N-terminal His6-tag 
and a TEV protease recognition site for removal of the tag. For ex-
pression of protein used for crystallization, the construct was trans-
formed into the E. coli Rosetta strain BL21(DE3)-R3, and cells were 
grown at 37°C in LB medium (Miller) supplemented with kanamy-
cin (50 mg/ml) and chloramphenicol (35 mg/ml). After reaching an 
optical density at 600 nm of 0.5 to 0.6, the temperature was lowered 
to 18°C before induction of protein expression overnight by adding 
0.5 mM IPTG. Harvested cells were resuspended in lysis buffer 
[50 mM Hepes (pH 7.5), 500 mM NaCl, 5% glycerol, 20 mM imidazole, 
10 mM bME, and cOmplete EDTA-free protease inhibitors (Roche)] 
and stored at −20°C until purification. For protein purification, pel-
lets were gently thawed in lukewarm water and lysed by high-pressure 
homogenization. DNA was digested using Benzonase. Proteins 
were purified by immobilized metal affinity chromatography (IMAC) 
using Ni-Sepharose resin (GE Healthcare) and eluted stepwise in 
binding buffer containing 40 to 500 mM imidazole. A high-salt wash 
with 1 M NaCl was combined with the first elution step including 
40 mM imidazole. Removal of the His6 tag was carried out by addi-
tion of recombinant TEV protease during overnight dialysis into buf-
fer without imidazole, followed by purification on a second IMAC 
column, and lastly by SEC (Superdex 75, GE Healthcare) in a buffer 
consisting of 20 mM Hepes (pH 8.0), 250 mM NaCl, and 2 mM 
DTT. Macrodomain protein used for HTRF assay was not sub-
jected to TEV cleavage and purified after the IMAC step by SEC in 
a buffer consisting of 25 mM Hepes (pH 7.4), 300 mM NaCl, 
5% glycerol, and 0.5 mM tris(2-carboxyethyl)phosphine. Proteins 
were characterized by SDS–polyacrylamide gel electrophoresis, 














































Schuller et al., Sci. Adv. 2021; 7 : eabf8711     14 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
19 of 23
Crystallographic fragment screening
SARS-CoV-2 Nsp3 Mac1 was concentrated to a final concentration 
of 47 mg/ml and apo crystals were grown in crystallization solution 
containing 100 mM CHES (pH 9.5) and 30% PEG-3000. Fragments 
were soaked into crystals as previously described (23) by adding dis-
solved compounds directly to the crystallization drops using an 
Echo liquid handler (final concentration, 10% DMSO); drops were 
incubated for approximately 1 to 3 hours before mounting and 
flash-freezing in liquid nitrogen.
Data were collected at the beamline I04-1 at 100 K and automati-
cally processed with Diamond Light Source’s autoprocessing pipe-
lines using XDS (57) and either xia2 (62) or DIALS (63) with the 
default settings. Most Mac1 data processed to a resolution of approx-
imately 1.1 Å. Further analysis was performed with XChemExplorer 
(24), electron density maps were generated with DIMPLE (66), and 
ligand-binding events were identified using PanDDA (39). Ligands 
were modeled into PanDDA-calculated event maps using Coot (59), 
restraints were calculated with AceDRG (69), and structures were re-
fined with BUSTER (70). Coordinates, structure factors, and PanDDA 
event maps for the structures discussed are deposited in the PDB. Data 
collection and refinement statistics are summarized in data file S1.
Molecular docking screens
Docking was performed against the crystal structure of SARS-CoV-2 
Nsp3 Mac1 bound to ADPr (PDB 6W02) (34). Chain B and all water 
molecules except for HOH324, HOH344, HOH384, and HOH406 
were removed. These water molecules were included in the docking 
template structure because they were buried within the ADPr-binding 
site and formed bridging hydrogen bonds between ADPr and the pro-
tein. The protein structure in complex with ADPr and the four selected 
water molecules was capped at N and C termini and prepared for 
docking following the prepwizard protocol in Maestro (Schrödinger) 
(71). Accordingly, protons were added using Epik, and protonation 
states were optimized with PropKa at pH 7. Last, the structure was en-
ergetically minimized using the OPLS3e force field (71). The maxi-
mum heavy-atom deviation from the initial structure was 0.3 Å (71).
Docking was performed with DOCK3.7 using precalculated scoring 
grids for rapid evaluation of docked molecules (72). AMBER united- 
atom charges (73) were assigned to the minimized protein structure 
and water molecules. Partial atomic charges of backbone amide hy-
drogen atoms for residues Ile23 and Phe156 were increased by 0.2 ele-
mentary charge units without changing the net charge of the residues, 
as described previously (29). The low dielectric constant of the protein 
environment was extended outwards from the protein surface by 
1.9 Å using spheres generated by Sphgen. Electrostatic potentials at 
the ligand-binding pocket were calculated by the numerical solution of 
the Poisson-Boltzmann equation using QNIFFT (74), and scoring grids 
for van der Waals potentials were generated with CHEMGRID. Li-
gand desolvation scoring grids were calculated by Solvmap (75), and 
the volume of the low-protein dielectric was extended out 0.4 Å from 
the protein surface, as described previously (40). Because we specifi-
cally targeted the adenosine-binding site of the full ADPr-binding 
pocket, atomic coordinates of adenosine rather than the whole ADPr 
molecule were used to generate 45 matching spheres, representing fa-
vorable positions for placing ligand atoms with docking (72).
As ADPr was the only known ligand for Mac1 when we started the 
docking campaign, the generated scoring grids and matching spheres 
were judged for their ability to place and score adenosine, adenine, 
and ribose at the adenosine-binding site of the ligand-binding pocket 
compared to 250 property-matched decoys, generated following the 
DUDE-Z method (76). Decoys share similar physical properties as 
the control molecules but are topologically different, hence unlikely 
to ligate the binding pocket. Furthermore, an “extrema” set (76) of 
approximately 500,000 molecules including anionic, neutral, and 
cationic compounds with molecular weights ranging from 250 to 
350 Da was screened to ensure similar enrichments for monovalent 
anions and neutral molecules. We note that the lack of experimentally 
confirmed ligands for the macrodomain did not allow exhaustive 
control calculations.
Virtual compound libraries were downloaded from ZINC15 
(http://zinc15.docking.org) (37). From the set of 722,963 in-stock 
fragments, 696,092 compounds were successfully docked, exploring 
on average 2355 orientations and 63 conformations per compound 
in the binding pocket. Roughly 58 billion complexes were sampled 
in 88 core hours or roughly 10 min on a 500-core cluster. Screening 
the entire 20 million ZINC15 fragment library resulted in the eval-
uation of ca. 4.4 trillion complexes within 2342 core hours or 4.7 hours 
on 500 cores. In that screen, 19,130,798 compounds were scored and 
sampled in ca. 2145 orientations and 180 conformations each. From 
the relatively small in-human library, containing 20,726 molecules, 
17,362 compounds were scored, and sampling was increased to 
roughly 16,615 orientations per compound. Eighty-four billion 
complexes were evaluated in 27 core hours.
Compounds with DOCK scores of <−20 (top 500,000 compounds 
from the entire fragment screen) were subsequently filtered for those 
with strained conformations and inspected for their ability to form 
hydrogen bonds to residues Asp22, Ile23, Gly48, Val49, Gly130, or Phe156. 
Compounds with unsatisfied hydrogen bond donors or more than 
three unsatisfied hydrogen bond acceptors were deprioritized. From 
both fragment screens, 17 in-stock compounds (8 selected from the 
ZINC15 in-stock library docking screen) were purchased, and 45 
make-on-demand fragments were ordered of which 33 were suc-
cessfully synthesized, both from Enamine. The following compounds 
were selected from the in-human collection docking screen and 
purchased from different vendors: pterin (Sigma-Aldrich, P1132), 
verdiperstat (MedChem Express, HY-17646), kinetin (Cayman 
Chemical, 20712), irsogladine (Cayman Chemical, 30223), diaveridine 
(Cayman Chemical, 29427), N6-benzyladenine (Cayman Chemical, 
21711), PP2 (Cayman Chemical, 13198), temozolomide (Cayman 
Chemical, 14163), chrysophanol (Cayman Chemical, 19870), and 
isoxanthopterin (Cayman Chemical, 17564).
Fragment linking and merging
Fragment mergers and linkers were generated using Fragmenstein 
(https://github.com/matteoferla/Fragmenstein), a python module 
that automatically joins fragments or places compounds based on 
fragments in a way that is as faithful to the positions of the frag-
ments as possible in a conformation that is energy acceptable. For 
merging, using RDKit (77), rings are temporarily collapsed into 
pseudo-atoms, one-to-one spatial overlapping atoms are identified; 
pseudo-atoms expanded with appropriate bonds to nearby atoms 
and various chemical corrections applied. For the constrained ener-
gy minimization, PyRosetta is used (78). Interactive online summa-
ry of mergers was made at https://michelanglo.sgc.ox.ac.uk (79).
Differential scanning fluorimetry
Compounds were dissolved in DMSO to a final concentration of 
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PP0200). Using a Labcyte Echo, each compound was dispensed 
into a 384-well storage plate (Greiner Bio-One, 781280) in five stock 
concentrations in twofold serial dilutions (compounds, 6.25 to 
100 mM; ADPr, 0.625 to 10 mM) and a final volume of 750 nl in 
triplicate. Two identical plates were created, with the second plate 
used to provide protein-free controls for all tested conditions. 
Echo dispensing instructions were created by an in-house app 
(https://gestwickilab.shinyapps.io/echo_layout_maker/).
DSF buffer was prepared by adding 10 ml of SYPRO Orange 
(Thermo Fisher Scientific, S6650) to 10 ml of buffer [50 mM tris-
HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.01% 
Triton X-100] for a final dye concentration of 5× (10 mM) SYPRO 
Orange. A compound plate (see above) was resuspended by the ad-
dition of 20 ml of DSF buffer and set aside for 20 min in the dark. 
Purified Mac1 (P43 construct purified at UCSF) was diluted to 10 mM 
in DSF buffer, and 2 ml of either protein solution or protein-free 
buffer was added to each well of a 384-well white PCR plate (Axygen, 
PCR-384-LC480WNFBC) using an E1 ClipTip P125 electronic pi-
pette. Eight microliters of resuspended compound was transferred 
to each well of the protein- and buffer-containing PCR plate using 
an Opentrons OT-2 liquid handling system, yielding the following 
final conditions: 2 mM Mac1, 5× (10 mM) SYPRO Orange, 3% DMSO, 
0.1 to 3 mM fragments, and 0.1 to 1 mM ADPr. The PCR plate was 
spun briefly in a salad spinner to remove bubbles and sealed with an 
optically clear film (Applied Biosystems, MicroAmp Optical Adhe-
sive Film, 4311971). In an Analytik Jena qTOWER 384G quantita-
tive PCR instrument, plate was continuously heated from 25° to 
94°C at a rate of 1°C/min, and fluorescence was measured at each 
degree in the TAMRA channel (535/580 nm). Fifty-three of 54 frag-
ments could be tested up to 3 mM without assay interference under 
these conditions (data files S1 and S2). Tma values were calculated 
online at DSFworld, using fitting model 2 (80).
Raw DSF data for the Mac1 construct used in this work were 
characterized by a major transition at 50.8° ± 0.3°C, with a minor 
second transition at 67° ± 4°C (Fig. 9, C and D, and data files S1 and 
S2); results described refer to the major transition. Significance was 
defined as compounds with analysis of variance (ANOVA) P < 0.005 
for Tma over the tested concentration regime.
Isothermal titration calorimetry
All ITC titrations were performed on a MicroCal iTC 200 instru-
ment (GE Healthcare). All reactions were performed in 20 mM tris 
(pH 7.5) and 150 mM NaCl using 300 to 600 mM Mac1 (P43 con-
struct purified at UCSF) at 25°C. Titration of 4 mM ADP-ribose 
(Sigma-Aldrich, A0752) or 4 to 10 mM fragment contained in the 
stirring syringe included a single 0.2-ml injection, followed by 18 
consecutive injections of 2 ml. Data were analyzed using the Micro-
Cal PEAQ-ITC analysis software v1.1.0.1262 (Malvern). Thermo-
grams were integrated and normalized binding enthalpies fitted to 
an equilibrium binding isotherm (nonlinear least squares fit) using 
a single-site binding model.
HTRF-based peptide displacement assay
Fragment inhibitory activity on Mac1 was assessed by the displace-
ment of an ADPr-conjugated biotin peptide from the His6-tagged 
Mac1 using HTRF with an Eu3+-conjugated anti-His6 antibody donor 
and streptavidin-conjugated acceptor. Compounds were dispensed 
into white ProxiPlate-384 Plus (PerkinElmer) assay plates using an 
Echo 525 liquid handler (Labcyte). Binding assays were conducted 
in a final volume of 16 ml with 12.5 nM Mac1, 400 nM peptide 
ARTK(Bio)QTARK(Aoa-RADP)S [synthesized by Cambridge Peptides 
(Birmingham, UK)], 1:125 streptavidin-XL665 (Cisbio), and 1:20,000 
anti–His6-Eu
3+ cryptate (PerkinElmer) in assay buffer [25 mM Hepes 
(pH 7.0), 20 mM NaCl, 0.05% bovine serum albumin, and 0.05% 
Tween 20]. Assay reagents were dispensed into plates using a Multidrop 
combi (Thermo Fisher Scientific) and incubated at room tempera-
ture for 1 hour. Fluorescence was measured using a PHERAstar mi-
croplate reader (BMG) using the HTRF module with dual-emission 
protocol (A = excitation of 320 nm, emission of 665 nm and B = 
excitation of 320 nm, emission of 620 nm). Raw data were processed 
to give an HTRF ratio (channel A/B × 10,000), which was used to 
generate IC50 curves by nonlinear regression using GraphPad Prism 
v8 (GraphPad Software, CA, USA).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/16/eabf8711/DC1
View/request a protocol for this paper from Bio-protocol.
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